Cargando…

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL

Detalles Bibliográficos
Autores principales:	Benjamini, Ohad, Tadmor, Tamar, Avigdor, Abraham, Gershon, Rotem, Klike, Limor, Atari, Nofar, Abdelkader, Bayan, Mandelboim, Michal, Rahav, Galia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology. Published by Elsevier Inc. 2022
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665240/ http://dx.doi.org/10.1182/blood-2022-167353

Ejemplares similares

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
por: Sutton, K, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
por: Hobbs, F. D. Richard, et al.
Publicado: (2023)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
por: Richard Hobbs, F D, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
por: Pulvirenti, Federica, et al.
Publicado: (2023)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic
por: Clegg, Lindsay E, et al.
Publicado: (2023)

PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY
por: Buquicchio, Caterina, et al.
Publicado: (2023)

COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders
por: Kaminski, Hannah, et al.
Publicado: (2022)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
por: Jondreville, Ludovic, et al.
Publicado: (2022)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
por: Dichtl, Stefanie, et al.
Publicado: (2022)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
por: Brady, Tyler, et al.
Publicado: (2022)

INCIDENCE OF COVID-19 INFECTIONS IN ADULTS WITH PRIMARY IMMUNODEFICIENCY AFTER RECEIVING TIXAGEVIMAB AND CILGAVIMAB
por: Johnson, S., et al.
Publicado: (2022)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases
por: Otiniano, Armelle, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Fernández-Prada, María, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4213ank6bfdeiajiqihvu718et